AI Telephone

James Brown is a male patient with a confirmed medication allergy record documenting no known drug allergies. His active, confirmed problem list includes stage 3b chronic kidney disease, diabetic nephropathy, type 2 diabetes mellitus, hypertension, and vitamin D deficiency. The chronic kidney disease is specifically documented as stage 3b and noted to be secondary to diabetic nephropathy. Supporting evidence includes a final eGFR observation of 38 mL/min/1.73 m2, interpreted as low, with documentation stating that the estimated glomerular filtration rate is 38 mL/min/1.73 m2.

Active medication orders include losartan 50 mg oral tablet, 50 mg by mouth once daily for renal protection, prescribed in relation to chronic kidney disease and hypertension; metformin 500 mg oral tablet, 500 mg by mouth twice daily for type 2 diabetes, with the dose reduced in the setting of chronic kidney disease; amlodipine 5 mg oral tablet, 5 mg by mouth once daily for blood pressure; and calcitriol 0.25 mcg oral capsule, 0.25 mcg by mouth once daily for vitamin D deficiency.

There is also an active service order for a basic metabolic panel, described as regular monitoring of renal function and electrolytes. This monitoring is indicated in the setting of stage 3b chronic kidney disease, diabetic nephropathy, and current medications, with a note stating that ongoing monitoring of renal function and electrolytes is required due to stage 3b CKD, diabetic nephropathy, and current medications.

James Brown, a male born in 1957, has no known drug allergies. His active medical conditions include chronic kidney disease stage 3B, diabetic nephropathy, type 2 diabetes mellitus, hypertension, and vitamin D deficiency. To manage his conditions, he is currently prescribed Losartan Potassium 50mg daily for chronic kidney disease, and Metformin Hydrochloride 500mg twice daily (noted as a reduced dose for CKD) for his type 2 diabetes mellitus. His hypertension is treated with Amlodipine 5mg daily, and he takes Calcitriol 0.25mcg daily for his vitamin D deficiency. Additionally, an active order has been placed for a basic metabolic panel (serum or plasma) to ensure regular monitoring of his renal function and electrolytes.

James Brown is a 67-year-old male with no known drug allergies (NKDA).

Active Diagnoses:

Mr. Brown carries a confirmed diagnosis of Stage 3b Chronic Kidney Disease (CKD), classified as severe, with a most recent estimated glomerular filtration rate (eGFR) of 38 mL/min/1.73m², which is significantly below the normal reference threshold of ≥90 mL/min/1.73m² (calculated using the CKD-EPI 2021 creatinine-based formula). The underlying etiology of his CKD is diabetic nephropathy, secondary to his confirmed diagnosis of Type 2 Diabetes Mellitus. He also has a confirmed diagnosis of essential hypertension.

Current Medications:

1. Losartan 50 mg oral tablet — 50 mg once daily, prescribed for renal protection in the setting of diabetic nephropathy with CKD stage 3b.
2. Metformin 500 mg oral tablet — 500 mg twice daily. The dose has been reduced from the standard dosing due to his CKD stage 3b (eGFR 38), with a note to monitor renal function regularly.
3. Amlodipine 5 mg oral tablet — 5 mg once daily for blood pressure control.
4. Calcitriol 0.25 mcg oral capsule — 0.25 mcg once daily for vitamin D deficiency associated with CKD.

Active Orders:

Two laboratory panels have been ordered for ongoing monitoring related to his CKD stage 3b:

• Renal function panel (serum/plasma) — to regularly monitor eGFR, creatinine, and BUN.
• Electrolyte panel (serum/plasma) — to regularly monitor sodium, potassium, chloride, and bicarbonate levels.

Summary:

Mr. Brown is a 67-year-old male with moderately advanced chronic kidney disease (stage 3b) driven by diabetic nephropathy in the context of type 2 diabetes mellitus, along with comorbid hypertension. His medication regimen reflects appropriate renal-dose adjustments, renoprotective therapy with an angiotensin receptor blocker, antihypertensive management, and supplementation for CKD-associated vitamin D deficiency. Ongoing laboratory surveillance of renal function and electrolytes has been ordered.

Clinical Summary for James Brown

James Brown is a 68-year-old male (DOB: May 15, 1956) with a complex medical history centered on chronic kidney disease (CKD) and its complications. His active medical conditions include:

• Stage 3b Chronic Kidney Disease (CKD) (diagnosed June 10, 2018), with a current eGFR of 38 mL/min/1.73m² (measured January 10, 2022), classified as severe and attributed to diabetic nephropathy.
• Type 2 Diabetes Mellitus (diagnosed March 22, 2010), contributing to his renal impairment.
• Hypertension (diagnosed November 5, 2008), a key modifiable risk factor for CKD progression.
• Vitamin D deficiency (diagnosed January 15, 2021), likely secondary to renal dysfunction.

Current Medications (all prescribed by Dr. Smith on January 10, 2022):

• Losartan 50mg orally daily for renal protection (angiotensin II receptor blocker, dose adjusted for CKD).
• Metformin 500mg orally twice daily (morning and evening) for glycemic control (dose reduced due to CKD).
• Amlodipine 5mg orally daily for blood pressure management.
• Calcitriol 0.25mcg orally daily for vitamin D deficiency (active vitamin D analog indicated in CKD).

Allergies: No known drug allergies (confirmed).

Monitoring Plan:

• Quarterly renal function tests (eGFR) to assess CKD progression.
• Quarterly electrolyte panels (sodium, potassium, chloride, bicarbonate) to monitor for CKD-related imbalances, particularly hyperkalemia given his use of losartan.

Key Considerations: Mr. Brown’s management reflects multimodal therapy for CKD with diabetes and hypertension, including renoprotective agents (losartan), glycemic control (metformin at reduced dose), and blood pressure management (amlodipine). His vitamin D deficiency is being treated with calcitriol, the active form preferred in CKD due to impaired renal 1α-hydroxylation. Close monitoring of renal function and electrolytes is critical to guide therapy adjustments and detect complications early. His lack of drug allergies simplifies pharmacologic management.

Clinical Narrative for James Brown

James Brown is a 67-year-old male with a complex medical history centered on chronic kidney disease (CKD) and its complications. His current active conditions include:

• Stage 3B Chronic Kidney Disease (CKD 3B) with an estimated glomerular filtration rate (eGFR) of 38 mL/min/1.73m², indicating moderately severe renal impairment.
• Diabetic nephropathy, reflecting kidney damage secondary to long-standing diabetes.
• Type 2 diabetes mellitus, contributing to his renal and cardiovascular risk profile.
• Hypertension, a key modifiable factor in his CKD progression.

His pharmacotherapy regimen is tailored to his renal function and comorbidities:

• Losartan 50mg daily for renal protection (angiotensin II receptor blocker to slow CKD progression).
• Metformin 500mg twice daily (dose-adjusted for CKD) for glycemic control in type 2 diabetes.
• Amlodipine 5mg daily for blood pressure management.
• Calcitriol 0.25mcg daily to address vitamin D deficiency, common in advanced CKD.

Allergy status is documented as no known drug allergies. A standing order exists for regular monitoring of renal function and electrolytes via basic metabolic panels to assess disease progression and medication safety. His care plan emphasizes nephroprotection, glycemic control, and cardiovascular risk reduction in the context of his multiorgan disease.

James Brown is a male patient born in 1958 who has no known drug allergies. He has an active diagnosis of Stage 3b chronic kidney disease secondary to diabetic nephropathy, which is supported by a recently documented low eGFR of 38 mL/min/1.73 m2. His other active medical conditions include Type 2 diabetes mellitus, essential hypertension, and vitamin D deficiency.

To manage his conditions, Mr. Brown's active medications include:

• Losartan 50 mg orally once daily, prescribed for renal protection in the setting of his chronic kidney disease.
• Metformin 500 mg orally twice daily for his Type 2 diabetes (noted as a reduced dose due to his chronic kidney disease).
• Amlodipine 5 mg orally once daily for blood pressure management.
• Calcitriol 0.25 mcg orally once daily for his vitamin D deficiency.

Additionally, there are active orders for routine laboratory testing, including a renal function panel and an electrolyte panel. Regular monitoring of his renal function and serum electrolytes has been requested due to his Stage 3b chronic kidney disease and his current antihypertensive therapy.

James Brown is a male patient born in 1958. He has a confirmed history of no known drug allergies. His active, confirmed medical problems include severe chronic kidney disease stage 3b (ICD-10 N18.32), with a note that this is secondary to diabetic nephropathy; diabetic renal disease/type 2 diabetes mellitus with diabetic nephropathy (ICD-10 E11.21); type 2 diabetes mellitus (ICD-10 E11.9); essential primary hypertension (ICD-10 I10); and vitamin D deficiency (ICD-10 E55.9).

Recent laboratory data include a final eGFR (CKD-EPI) of 38 mL/min/1.73 m2, which is interpreted as low, with a stated normal reference range of at least 90 mL/min/1.73 m2. This eGFR value is also documented in the CKD note. Active medication orders include losartan potassium 50 mg oral tablet, 50 mg by mouth once daily for renal protection, prescribed in the setting of chronic kidney disease and diabetic nephropathy; metformin hydrochloride 500 mg oral tablet, 500 mg by mouth twice daily for type 2 diabetes mellitus, with the dose reduced due to CKD stage 3b and eGFR 38, and a note to monitor renal function regularly; amlodipine 5 mg oral tablet, 5 mg by mouth once daily for blood pressure control; and calcitriol 0.25 mcg by mouth once daily for vitamin D deficiency.

There are also active service orders for ongoing CKD stage 3b monitoring, including a renal function panel and an electrolyte panel. Notes indicate that regular renal function and electrolyte monitoring are required as part of management of CKD stage 3b.

James Brown is a 69-year-old male (date of birth: May 15, 1956) with no known drug allergies.

Active Problem List:

Mr. Brown carries three confirmed, active diagnoses. He has a longstanding history of hypertension, diagnosed in November 2005, and type 2 diabetes mellitus, diagnosed in May 2010. He subsequently developed Stage 3b chronic kidney disease (CKD), with onset in January 2018, attributed to diabetic nephropathy. The CKD is classified as severe, with a most recent estimated glomerular filtration rate (eGFR) of 38 mL/min/1.73m², measured on October 15, 2023.

Current Medications (all ordered by Dr. Smith on January 15, 2023):

1. Losartan 50 mg oral tablet — 50 mg by mouth once daily, prescribed for renal protection in the setting of chronic kidney disease.
2. Metformin 500 mg oral tablet — 500 mg by mouth twice daily, prescribed for type 2 diabetes mellitus. Of note, the dose has been reduced due to his CKD.
3. Amlodipine 5 mg oral tablet — 5 mg by mouth once daily, prescribed for hypertension.
4. Calcitriol 0.25 mcg oral capsule — 0.25 mcg by mouth once daily, prescribed for vitamin D deficiency.

Standing Orders:

A recurring laboratory panel for renal function and electrolytes — including serum creatinine, potassium, sodium, and eGFR — has been ordered every 3 months by Dr. Smith for ongoing monitoring of his chronic kidney disease.